Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Note: Generex has a huge head start already funded by the Chinese. They will be able to test in China with less restrictions vs the FDA. Human trials in China with prior exposure to Covid -19 will start almost immediately. The vaccine if successful will put pressure for FDA Approval and a huge upside for Generex.
Epivax Info: Generex Partner EpiVax doing lab work both in Wuhan, China and Ross Labs at the University of Georgia.
EpiVax worked for 21 years to be able to make a vaccine in 24 hours!
https://epivax.com/
I do see construction and Government red tape does take time and oh yes India Shut down due to CV-19
Typical calling the Govt of India BS. Wow.
China Companies Contract Generex for Covid-19 Vaccine/
Sent to my e-mail Wealth Creation Investor
Fellow Investor,
The word on the street is this undiscovered company may have the solution to stop Coronavirus dead in its’ tracks.
Frankly, I’m expecting that the FDA will “fast track” this new vaccine. And testing is already underway in China.
Click here to download your FREE special report.
The Wall Street Journal reports that this drug is helping Covid-19 patients in critical condition.
ONLY a coronavirus vaccine can STOP this health crisis. And this undiscovered stock may already have the cure.
Shares could easily give you 209% profits – even when the stock market drops.
>>> Go here for your urgent report.
Ian Wyatt
P.S. Oh, and the gains could be even bigger.
Because the typical biotech stock jumps 773% during an outbreak. So, there could be much more upside.
Don’t wait – go here to download your PDF.
(Note: I believe I know the "stock")
https://tips.wyattresearch.com/cv-stock-alerts/?utm_source=Darwin&utm_medium=dedicated&utm_campaign=CoronaVirus%20leadgen&utm_term=Corona%20ad1%20SL3%20202003&utm_content=1086
This is a communication from Wyatt Investment Research.
We encourage you to review our full privacy policy.
Wyatt Investment Research
65 Railroad Street
PO Box 790
Richmond, Vermont 05477
https://www.google.com/search?client=firefox-b-1-d&q=Wall+street+journal+New+generex+covid+19
QMC is still around and hiring.
K&L Gates Loses hahahaha, Layoffs are coming
Bought some Hahahaha
1)Having court cases in 3 states was a distraction especially when this was such a trivial matter in the first place K&L Gates was dead wrong.
2)Amtron Not QMC is building India, QMC got 1.2 Mil and 1 Mil for 2 reactors which are off site.
3)QMC Hires 2 CTO CRO for up-coming QD Blockchain.
4)Corona Virus Hits.
Not getting off that easy FACTS MATTER
Did you ever consider that QMC went on HOLD to put this BS K&L Gates off their back. As pointed out it's up to Amtron to Build India. So it's no big deal to rest easy on the Pinks while all this other crap settles just in time for Covid-19.
Looking forward to hearing more about this cutting edge company which is very close to revealing itself and clean up the Nevada Reg's and loose the CE once and for all. I wonder if these gentleman follow developments on I-Hub?
India Blockchain QD's Mimms Winns Again. Next
Signed Sealed Delivered by POS K&L Gates
K&L Funded
K&L Funded
K&L Funded
They would never do that lol.
Anyone else have a Contract with China for a Vaccine/No. Generex is so overlooked.
Nice buy for longer term. Nice pipeline. Found this doing some DD on REIT NRZ.
Generex’s Ii-Key peptide vaccines for infectious disease and cancer have been studied in human clinical trials involving over 300 subjects in Phase I and Phase II clinical trials
See publications at https://generex.com/covid-19
Company: EpiVax/
Vaccine candidate: Ii-Key peptide vaccine
Details: EpiVax is developing two Ii-Key peptide vaccine candidates against COVID-19.
Status: EpiVax’s CEO said a vaccine could be ready within 5-6 months if the company receives the right level of funding.
Generex Partner/
Dude everything is shutting down currently for CV-19 Have a greaT DAY.
1-15 more like 1-2 with China Funding. Royalties they must know something after all they supply the US with most of mfg drugs.
We have different patience levels. Yse I am holding a bag, so. That is my Business. The w.rld is dealing with Covid-19. Things are in a disarray in case you had'nt noticed.
I dropped that shadow.
3/20/20 Judges side with QMC.
The decision sends the case back to the trial court.
Will K&L Gates settle outside of a trial?
Thanks doc Discounts are in Isle 5 and 4. Whats not to like besides Exposure. Holding.
MILV Yeeesss Found a 2 Nice REITs insides buying they went on heavy sale last week NRZ CIM / Money Injected Great place to Park Money in a dt.
Many 10K 30K late today slaps lately.
They need to get the OTC straightened Out. Foremost Im sure you understand this probably better than myself.
Have you been on contact at all injecting any ideas or suggestions that they also have I-Hub's eyeballs and the MLIV Army lol.
Once the dust turns into silver that wound be sweet,
http://stockcharts.com/c-sc/sc?s=NRZ&p=D&st=2013-05-02&en=(today)&i=t36275682205&r=1368753670695
Yummy Nice Close
Been slappin today for 10K. My broker likes me :)
The s/p needle is thud. This company with it's Contract with China is ahead of every other company to get a vaccine out there IMO. Too bad we are on the OTC however if Generex strikes gold look out many here who are waiting may be able to retire. Doc I know you read every post could you sticky today's this is an important update. thx
Generex has a contract with China and it is the biggest market of all. Scientists say that the virus is not really over in China. There is a good possibility of a second wave when they inevitably relax the quarantines.
And if we are successful with the vaccine in China, the whole world will beat a path to our door - no advertising will be necessary at that point. And that is less than 120 days away.
initiate human clinical trials in 3 to 5 months depending on regulatory agency requirements. We have vaccinated over 300 people with Ii-Key vaccines to demonstrate their safety and their ability to activate the immune response against peptide epitopes. As a public service to expedite the review of the Ii-Key vaccine technology by interested parties, we are providing a summary of safety on our Ii-Key development program from both published peer-reviewed literature as well as from our clinical investigator brochures on our website at Generex.com.”
https://generex.com/covid-19
We are advancing the coronavirus project with our partners in China, and we are available to partner with other countries to develop and commercialize our Ii-Key-SARS-2 vaccine. To date we have been in touch with the VA, BARDA, and HHS in the United States, and we are in communication with the Canadian Ministry of Health, as well as with authorities in Greece, England, Saudi Arabia, Iceland, Indonesia, Philippines, Italy, and Romania for licensing our Ii-Key-SARS-2 peptide vaccines as well as new, patented immunotherapy technology that will provide those countries with co-ownership of the Intellectual Property in their territories. We have engaged Morris L. Reid of Mercury LLC (http://mercuryllc.com) to advise the company on international licensing strategy.”
Generex Biotechnology Corporation has been working to develop a peptide vaccine against the new coronavirus SARS-CoV-2 using the company’s proprietary and patented Ii-Key immune system activation technology. We have built our technology to assist third party groups and government agencies in their evaluation of potential vaccines against this pandemic SARS-CoV-2 virus.
The patented NuGenerex Immuno-Oncology (Formerly Antigen Express) Ii-Key technology uses synthetic peptides that mimic essential protein regions from a virus that are chemically linked to the 4-amino acid Ii-Key to ensure robust immune system activation. In particular, the Ii-Key ensures potent activation of CD4+ T cells, which in turn facilitates antibody production to ward off infection. This Ii-Key modification can be applied to any protein fragment of any pathogen to increase the potency of immune stimulation.
Generex is working with our partners at EpiVax who have identified such protein fragments or epitopes to generate Ii-Key-SARS 2 peptide vaccines in collaboration with our peptide manufacturing partners. The peptides and Ii-Key are made from naturally occurring amino acids, ensuring an excellent safety profile for Ii-Key peptide vaccines.
For further information from government or corporate inquiries please email covid-19@nugenerexio.com